During open enrollment, choose San Diego's best health care. Get started.

About Ayad Hamdan, MD

Ayad Hamdan, MD, is a board-certified hematologist who specializes in treating people with cancers of the blood and lymph system, including lymphoma, multiple myeloma, leukemia, myeloproliferative neoplasms and myelodysplastic syndromes. He offers chimeric antigen receptor (CAR) T-cell therapy to adults with relapsed or refractory B-cell lymphoma, a type of non-Hodgkin lymphoma. CAR T-cell therapy harnesses the patient's own immune cells to recognize and kill cancer cells. It is just one of many types of personalized cancer therapies offered at UC San Diego Health.

As a physician in UC San Diego Health's Blood and Marrow Transplant Program, Dr. Hamdan provides comprehensive blood and marrow transplant services, including autologous and allogeneic stem cell transplantation for all hematologic malignancies, with a focus on B cell Non-Hodgkin's lymphoma and Hodgkin's lymphoma. In addition, Dr. Hamdan's clinical expertise and research interests include apheresis (stem cell collections), clinical innovation and quality improvement.

In 2023, Dr. Hamdan was appointed as physician-in-chief of Moores Cancer Center and cancer services, overseeing clinical operations and all related inpatient and outpatient oncology services at UC San Diego Health as well as operations with affiliates and outreach clinics.

As a professor in the Department of Medicine, he trains medical students, residents and fellows at UC San Diego School of Medicine. Dr. Hamdan has co-authored numerous articles and his work has appeared in medical and research publications, including Blood Journal, Lancet Hematology, Transfusion, Journal of Clinical Oncology, Journal of Immunotherapy and the Journal of Infectious Diseases.

Prior to joining UC San Diego Health, Dr. Hamdan was an attending physician at Beth Israel Deaconess Medical Center, Harvard Medical School, in Boston. He was also the site investigator for the HIV/AIDS Malignancy Consortium (a National Cancer Institute-supported clinical trials group) at Beth Israel Deaconess Medical Center, as well as the medical director for apheresis and infusion services.

Dr. Hamdan completed a fellowship in hematology and oncology through the Beth Israel Deaconess Medical Center Harvard Medical School program and his residency in internal medicine at Case Western Reserve University School of Medicine. He holds a medical degree from the American University of Beirut Medical Center in Beirut, Lebanon. He is board certified in hematology and internal medicine.

Dr. Hamdan is a member of the American Society of Apheresis, American Society of Hematology and American Medical Association.

He is fluent in Arabic.

UC San Diego Health Links

For more information, see Blood Cancers and Cancer Care.

Medical DegreeAmerican University of Beirut (AUB), Beirut, LebanonResidencyCase Western Reserve University, School of Medicine, Cleveland, OHFellowshipHarvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA
GenderMale
LanguagesArabic
Date Joined Staff2019-09-01
Board Certifications
American Board of Internal MedicineHematology
Conditions and Treatments
  • Blood Cancer
  • Blood and Marrow Stem Cell Transplantation
  • Allogeneic Stem Cell Transplant
  • Autologous Stem Cell Transplant
  • Hodgkin's Disease
  • Chimeric Antigen Receptor (CAR) T-Cell Therapy
  • Multiple Myeloma
  • Leukemia
  • Lymphoma
  • Advanced Myelodysplastic Syndromes
  • Advanced Myeloproliferative Neoplasms
  • Apheresis
  • Stem Cells
Cancer

Is My Insurance Accepted?

We accept most major insurance plans at UC San Diego Health. Find out if your insurance is accepted.

Open Payments Program Notification

For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.

View Open Payments Data for Dr. Hamdan